drugset / Trial / NCT06814132

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

NCT06814132

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.

Timeline

Start
2025-04-07
Primary completion
2025-10-04
Completion
2025-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Opevesostat Small molecule Oral
Background Fludrocortisone Other / unclassified Oral
Background Prednisone Other / unclassified Oral